Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy)....

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT) gets a 3% premarket lift from an initiation at Needham (Buy). Analyst Chad Messer is positive on eteplirsen and says he believes "the market reacted inappropriately to last week's regulatory update." The FDA requested "additional information" last Monday in order to evaluate an Accelerated Approval application, news the market did not like. (See also: Leerink Swann uncertain about SRPT)